**Supplemental Table 1.** Test characteristics of pre-dose #2 and pre-dose #3 infliximab concentration cut-offs with week 8 clinical remission

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Infliximab concentration****(ug/mL)** | **Sensitivity** **(%)** | **Specificity (%)** | **Positive predictive value** **(%)** | **Negative predictive value** **(%)** |
| Pre-dose #2 ≥ 31≥ 32≥ 33≥ 34≥ 35 | 66.762.562.558.358.3 | 60.060.066.770.070.0 | 80.079.083.382.482.4 | 42.940.040.041.241.2 |
| Pre-dose #3≥ 12≥ 13≥ 14≥ 15 ≥ 16 | 91.787.587.587.583.3 | 30.030.030.030.030.0 | 75.975.075.075.074.07 | 60.050.050.050.050.0 |

IFX – infliximab, AUROC – area under receiver operator curve